ClinicalTrials.gov
ClinicalTrials.gov Menu

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00055731
Recruitment Status : Active, not recruiting
First Posted : March 7, 2003
Last Update Posted : May 17, 2018
Sponsor:
Collaborators:
Sanofi
AstraZeneca
Information provided by (Responsible Party):
UNICANCER

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : December 2010
  Estimated Study Completion Date : December 2021
Publications of Results:
Fizazi K, Lesaunier F, Delva R, et al.: A phase III trial of docetaxel-estramustine in high-risk localized prostate cancer (GETUG 12 trial): design, tolerance, response, and quality of life (QOL). [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-7, 2010.
Fizazi K, Gravis G, Culine S: The GETUG 12 trial, a phase III randomized trial of docetaxel-estramustine in high-risk localized prostate cancer: clinical design and current status. [Abstract] 2006 Prostate Cancer Symposium, February 24-26, 2006, San Francisco, CA. A-153, 2006.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):